May was a terrible month for biotech, but June is (early days) looking better.

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion." ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Stocks were rising Tuesday and the Nasdaq Composite turned higher for the year even as uncertainty over global trade ...

Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases ...

MoonLake Immunotherapeutics is a Cayman Islands domiciled, Zug, Switzerland headquartered clinical-stage biopharmaceutical concern focused on the development of its sonelokimab (SLK) therapy to ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

In trading on Tuesday, shares of MoonLake Immunotherapeutics (Symbol: MLTX) crossed above their 200 day moving average of $45.66, changing hands as high as $49.48 per share. MoonLake ...